This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Beyonttra Banner.

Recorded webinars

Expert Insights into ATTR-CM

Recorded 2026

Session 1 & 2
 |  
Session 3 & 4
|  
Session 5 & 6

ATTR-CM with
Dr. Neasa Starr and Prof. Carsten Tschöpe

Welcome to our exclusive video series featuring Dr. Neasa Starr, as she engages in an insightful interview with Prof. Carsten Tschöpe, a renowned expert in cardiac amyloidosis. This series explores the complexities of ATTR-CM. Join us in a discussion on diagnosis, treatment, and the importance of a multidisciplinary approach in managing this challenging condition.
 

The

6 separate sessions
can be viewed below.

Dr. Neasa Starr

Dr. Neasa Starr_photo2

Consultant Cardiologist, University Hospital Limerick 

Professor Carsten Tschöpe

Professor Carsten Tschöpe_photo

Professor of Medicine and Cardiology, Charité University Hospital Berlin

Session 1

  • In this video, Dr. Neasa Starr and Prof. Carsten Tschöpe discuss the key red flag symptoms that healthcare providers should be aware of when diagnosing ATTR-CM. Understanding these symptoms is crucial for timely intervention and effective management of the disease. 

Duration time
| 03:14 minutes

Session 2

  • Dr. Starr and Prof. Tschöpe explore the significance of a multidisciplinary team (MDT) approach in the diagnosis and treatment of cardiac amyloidosis. They emphasize how collaboration among specialists can enhance patient outcomes and ensure comprehensive care.

Duration time
| 01:10 minutes


Beyonttra®▼ (acoramidis) Prescribing Information

Session 3

  • In this discussion, Dr. Starr and Prof. Tschöpe examine the gender differences observed in cardiac amyloidosis. They discuss how these differences can impact diagnosis, as well as overall patient care.

Duration time
| 03:39 minutes

Session 4

  • Join Dr. Starr and Prof. Tschöpe as they review the current treatment options available for ATTR cardiac amyloidosis.

Duration time
| 05:45 minutes

Beyonttra®▼ (acoramidis) Prescribing Information

Session 5

  • Join Dr. Starr and Prof. Tschöpe as they discuss promising future therapies. This video provides valuable insights into the evolving landscape of treatment strategies for this complex condition. 

Duration time
| 03:38 minutes

Session 6

  • In the final video of the series, Dr. Starr and Prof. Tschöpe address the critical question of patient involvement in discussions about their care. They highlight the importance of including patients in the conversation to improve treatment adherence and outcomes.

Duration time
| 02:18 minutes


Beyonttra®▼ (acoramidis) Prescribing Information

 

PP-PF-CAR-IE-0017-1 | April 2026